Abbott Laboratories reported strong Q2 2025 financial performance, with 6.9% sales growth, 11% adjusted EPS increase, and 100 basis point margin expansions in gross and operating margins. Medical Devices sales rose 12%, driven by diabetes care, heart failure, and electrophysiology, while Nutrition sales grew 3.5%. Diagnostics sales declined 1.5% due to COVID testing and China procurement impacts. The company faces headwinds from tariffs, foreign exchange, and HIV testing funding changes, but remains optimistic about 2026 growth.

Abbott is expanding its structural heart market, particularly in TAVR valve replacements, following Boston Scientific's exit from the TAVR space. The company reported strong sales growth for its Navitor transcatheter aortic valve replacement implant, with a 13% year-over-year increase in structural heart revenue. Abbott also announced plans for a new cardiovascular manufacturing facility in Georgia and secured FDA approval for its Tendyne mitral valve replacement implant. The company is developing a new balloon-expandable TAVR implant and advancing a dual-sensor CGM platform for diabetes care.

Abbott and Medtronic, two major medtech companies, announced a partnership to collaborate on diabetes management systems combining Abbott's FreeStyle Libre CGMs with Medtronic's insulin delivery technology. The partnership includes FDA submission of an interoperable pump, new app features for CGM data, and integration with Apple Watch and Epic EHR. The collaboration aims to improve patient care through shared innovation in diabetes technology.

The Copenhagen Declaration, launched in 2024, aims to transform diabetes prevention and care globally by promoting collaboration, research, and equitable access, particularly in low- and middle-income countries.

Abbott is expanding its diabetes business through partnerships, developing a dual glucose-ketone sensor, and leveraging ADA guidelines to improve access to continuous glucose monitoring (CGM) for Type 2 diabetes patients. The company is collaborating with Medtronic, Tandem Diabetes Care, and Sequel Med Tech to integrate new technologies and address unmet medical needs in diabetes management.